Mimedx (MDXG) Research & Development (2011 - 2026)
Mimedx (MDXG) posted Research & Development of $2.8 million for Q2 2026, down 32.92% sequentially from $4.1 million in Q1 2026, and down 15.92% YoY from $3.3 million in Q2 2025.
Mimedx (MDXG) Research & Development (2011 - 2026) Analysis & Trends
Mimedx has reported Research & Development for 16 years, with the latest figure at $2.8 million in Q2 2026.
- Quarterly Research & Development fell 15.92% year-over-year to $2.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $15.4 million (up 17.23% YoY) and the FY2025 annual result came in at $15.1 million, up 22.33% from the prior year.
- Research & Development slipped to $2.8 million in Q2 2026 per MDXG's latest filing, from $4.1 million in the prior quarter.
- Over five years, Research & Development peaked at $6.0 million in Q1 2022 and troughed at -$4.7 million in Q4 2022.
- A 5-year average of $3.3 million and a median of $3.4 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development slumped 66.6% in 2022, then soared 151.46% in 2023.
- Over 5 years, Research & Development stood at -$4.7 million in 2022, then jumped by 151.46% to $2.4 million in 2023, then surged by 46.77% to $3.6 million in 2024, then jumped by 33.32% to $4.8 million in 2025, then tumbled by 41.67% to $2.8 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $2.8 million, $4.1 million, and $4.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | 2.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.78 Mn |
| Mar 31, 2026 | 4.14 Mn |
| Dec 31, 2025 | 4.76 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 3.30 Mn |
| Mar 31, 2025 | 3.33 Mn |
| Dec 31, 2024 | 3.57 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 3.01 Mn |
| Mar 31, 2024 | 2.84 Mn |
| Dec 31, 2023 | 2.43 Mn |
| Sep 30, 2023 | 3.08 Mn |
| Jun 30, 2023 | 3.67 Mn |
| Mar 31, 2023 | 3.48 Mn |
| Dec 31, 2022 | -4.73 Mn |
| Sep 30, 2022 | 5.95 Mn |
| Jun 30, 2022 | 5.51 Mn |
| Mar 31, 2022 | 5.96 Mn |
| Dec 31, 2021 | -2.84 Mn |
| Sep 30, 2021 | 4.37 Mn |